Search

Your search keyword '"Jordan, Emmet"' showing total 184 results
Start Over Author "Jordan, Emmet"
184 results on '"Jordan, Emmet"'

5. Second‐line chemotherapy in advanced biliary cancers: A retrospective, multicenter analysis of outcomes

Author

Lowery, Maeve A, Goff, Laura W, Keenan, Bridget P, Jordan, Emmet, Wang, Rui, Bocobo, Andrea G, Chou, Joanne F, O’Reilly, Eileen M, Harding, James J, Kemeny, Nancy, Capanu, Marianela, Griffin, Ann C, McGuire, Joseph, Venook, Alan P, Abou‐Alfa, Ghassan K, and Kelley, Robin K

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Clinical Research, Cancer, Digestive Diseases, Digestive Diseases - (Gallbladder), Liver Disease, Clinical Trials and Supportive Activities, Rare Diseases, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Biliary Tract Neoplasms, Female, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Neoplasm Metastasis, Neoplasm Staging, Retreatment, Retrospective Studies, Treatment Failure, Treatment Outcome, Young Adult, biliary cancer, bile duct cancer, chemotherapy, cholangiocarcinoma, gallbladder cancer, second line, Public Health and Health Services, Oncology & Carcinogenesis, Oncology and carcinogenesis, Public health
Abstract

BackgroundAlthough gemcitabine plus platinum chemotherapy is the established first-line regimen for advanced biliary cancer (ABC), there is no standard second-line therapy. This study evaluated current practice and outcomes for second-line chemotherapy in patients with ABC across 3 US academic medical centers.MethodsInstitutional registries were reviewed to identify patients who had received second-line chemotherapy for ABC from April 2010 to March 2015 along with their demographics, diagnoses and staging, treatment histories, and clinical outcomes. Overall survival from the initiation of second-line chemotherapy (OS2) was estimated with Kaplan-Meier methods.ResultsThis study identified 198 patients with cholangiocarcinoma (intrahepatic [61.1%] or extrahepatic [14.1%]) or gallbladder carcinoma (24.8%); 52% received at least 3 lines of systemic chemotherapy. The median OS2 was 11 months (95% confidence interval [CI], 8.8-13.1 months). The median OS2 for patients with intrahepatic cholangiocarcinoma was 13.4 months (95% CI, 10.7-17.8 months), which was longer than that for patients with extrahepatic cholangiocarcinoma (6.8 months; 95% CI, 5-10.6 months) or gallbladder carcinoma (9.4 months; 95% CI, 7.2-12.3 months; P = .018). The median time to second-line treatment failure was 2.2 months (95% CI, 1.8-2.7 months), and it was similar across tumor locations (P = .60).ConclusionsIn this large cohort of patients with ABC treated across 3 academic medical centers after the failure of first-line chemotherapy, the time to treatment failure on standard therapies was short, although the median OS2 was longer than has been reported previously, and more than half of the patients received additional lines of treatment. This multicenter collaboration represents the largest cohort studied to date of second-line chemotherapy for ABC and provides a contemporary benchmark for future clinical trials.

Published
2019

6. Pregnancy-associated breast cancer: evaluating maternal and foetal outcomes. A national study

Author

Prior, Lisa, O’Dwyer, Richard, Farooq, Abdul Rehman, Greally, Megan, Ward, Cian, O’Leary, Connor, Aslam, Razia, Darwish, Waseem, Ahmed, Nada, Othman, Elly Che, Watson, Geoffrey, Kelly, Deirdre, Gleeson, Jack, Kiely, Lisa, Hassan, Anees, Walsh, Elaine M., O’Reilly, David, Jones, Alfred, Featherstone, Hannah, Lim, Marvin, Murray, Hazel, Hennessy, Bryan T., Smyth, Lillian M., Leonard, Gregory, Grogan, Liam, Breathnach, Oscar, Calvert, Paula, Horgan, Anne M., Coate, Linda, Jordan, Emmet J., O’Mahony, Deirdre, Gupta, Rajnish, Keane, Maccon M., Westrup, Jennifer, Duffy, Karen, O’Connor, Miriam, Morris, Patrick G., Kennedy, M. John, O’Reilly, Seamus, McCaffrey, John, Kelly, Catherine M., Carney, Desmond, Gullo, Giuseppe, Crown, John, Higgins, Michaela J., Walsh, Paul M., and Walshe, Janice M.

Published
2021
Full Text
View/download PDF

7. Frequency of next-generation sequencing, prevalence of targetable mutations and response to targeted therapies amongst patients with metastatic urothelial cancer in Ireland: a multi-centre retrospective study of real-world data.

Author

Ronan, Karine, Jordan, Emmet, Leonard, Christine, and McDermott, Ray

Abstract

Background: The genomic knowledge on urothelial carcinoma is expanding. It is recognised that urothelial carcinoma is a disease with a high somatic mutation rate and a high prevalence of genetic alterations, as discussed by Thomas and Sonpavde (2022). In the context of a disease rich with somatic alterations, continuing efforts to better identify which patients may benefit most from targeted therapy, immunotherapy and combination therapy may ultimately lead to improved outcomes for patients with this disease. Aims: We aimed to ascertain the frequency of next-generation sequencing (NGS) and the prevalence of genomic alterations amongst patients with metastatic urothelial cancer (mUC) in Ireland. We studied patients who received a targeted therapy following the detection of an oncogenic alteration on NGS and assessed their outcomes. Methods: Patients with a diagnosis of mUC between 2017 and 2022 were identified from Urology MDT databases as well as pharmacy databases across three Irish cancer centres. A retrospective review of patient notes including a comprehensive review of histopathology, radiology data, prior therapies and NGS reports was carried out for each patient. Results: 111 patients diagnosed with mUC between 2017 and 2022 were identified for inclusion across three hospital sites. NGS was carried out on the tumour specimens of 66 patients (59%). Thirty-six potentially therapeutically targetable alterations were identified amongst thirty-five patients. The most frequent alterations identified were PIK3CA mutations, FGFR3 mutations or fusions and ERBB2 somatic mutations. Fifteen patients (13.5%) received therapy directed at a genetic alteration. The most common targeted therapy received was erdafitinib (60%) followed by trastuzumab (33%) with one patient receiving alpelisib monotherapy. The median duration of treatment with targeted therapy was 3 months (range 1–34 months). Two patients were observed to have durable responses to erdafitinib approaching 3 years duration. Conclusions: This study provides an understanding of the use of NGS and prevalence of genomic alterations in an Irish patient population. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

8. Clinical and Genomic Characterization of Bladder Carcinomas With Glandular Phenotype

Author

Almassi, Nima, Whiting, Karissa, Toubaji, Antoun, Lenis, Andrew T., Jordan, Emmet J., Won, Helen, Regazzi, Ashley M., Chen, Ying-Bei, Gopalan, Anuradha, Sirintrapun, Sahussapont J., Fine, Samson W., Tickoo, Satish K., Ostrovnaya, Irina, Pietzak, Eugene J., Cha, Eugene K., Goh, Alvin C., Donahue, Timothy F., Herr, Harry W., Donat, S. Machele, Dalbagni, Guido, Bochner, Bernard H., Teo, Min Yuen, Funt, Samuel A., Rosenberg, Jonathan E., Reuter, Victor E., Bajorin, Dean F., Solit, David B., Al-Ahmadie, Hikmat, and Iyer, Gopa

Published
2022
Full Text
View/download PDF

10. YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics

Author

Fan, Pang-Dian, Narzisi, Giuseppe, Jayaprakash, Anitha D., Venturini, Elisa, Robine, Nicolas, Smibert, Peter, Germer, Soren, Yu, Helena A., Jordan, Emmet J., Paik, Paul K., Janjigian, Yelena Y., Chaft, Jamie E., Wang, Lu, Jungbluth, Achim A., Middha, Sumit, Spraggon, Lee, Qiao, Huan, Lovly, Christine M., Kris, Mark G., Riely, Gregory J., Politi, Katerina, Varmus, Harold, and Ladanyi, Marc

Published
2018

12. Tumor mutational load predicts survival after immunotherapy across multiple cancer types

Author

Samstein, Robert M., Lee, Chung-Han, Shoushtari, Alexander N., Hellmann, Matthew D., Shen, Ronglai, Janjigian, Yelena Y., Barron, David A., Zehir, Ahmet, Jordan, Emmet J., Omuro, Antonio, Kaley, Thomas J., Kendall, Sviatoslav M., Motzer, Robert J., Hakimi, A. Ari, Voss, Martin H., Russo, Paul, Rosenberg, Jonathan, Iyer, Gopa, Bochner, Bernard H., Bajorin, Dean F., Al-Ahmadie, Hikmat A., Chaft, Jamie E., Rudin, Charles M., Riely, Gregory J., Baxi, Shrujal, Ho, Alan L., Wong, Richard J., Pfister, David G., Wolchok, Jedd D., Barker, Christopher A., Gutin, Philip H., Brennan, Cameron W., Tabar, Viviane, Mellinghoff, Ingo K., DeAngelis, Lisa M., Ariyan, Charlotte E., Lee, Nancy, Tap, William D., Gounder, Mrinal M., D’Angelo, Sandra P., Saltz, Leonard, Stadler, Zsofia K., Scher, Howard I., Baselga, Jose, Razavi, Pedram, Klebanoff, Christopher A., Yaeger, Rona, Segal, Neil H., Ku, Geoffrey Y., DeMatteo, Ronald P., Ladanyi, Marc, Rizvi, Naiyer A., Berger, Michael F., Riaz, Nadeem, Solit, David B., Chan, Timothy A., and Morris, Luc G. T.

Published
2019
Full Text
View/download PDF

13. Data from Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies

Author

Jordan, Emmet J., primary, Kim, Hyunjae R., primary, Arcila, Maria E., primary, Barron, David, primary, Chakravarty, Debyani, primary, Gao, JianJiong, primary, Chang, Matthew T., primary, Ni, Andy, primary, Kundra, Ritika, primary, Jonsson, Philip, primary, Jayakumaran, Gowtham, primary, Gao, Sizhi Paul, primary, Johnsen, Hannah C., primary, Hanrahan, Aphrothiti J., primary, Zehir, Ahmet, primary, Rekhtman, Natasha, primary, Ginsberg, Michelle S., primary, Li, Bob T., primary, Yu, Helena A., primary, Paik, Paul K., primary, Drilon, Alexander, primary, Hellmann, Matthew D., primary, Reales, Dalicia N., primary, Benayed, Ryma, primary, Rusch, Valerie W., primary, Kris, Mark G., primary, Chaft, Jamie E., primary, Baselga, José, primary, Taylor, Barry S., primary, Schultz, Nikolaus, primary, Rudin, Charles M., primary, Hyman, David M., primary, Berger, Michael F., primary, Solit, David B., primary, Ladanyi, Marc, primary, and Riely, Gregory J., primary

Published
2023
Full Text
View/download PDF

14. Supplementary Figure 5 from Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies

Author

Jordan, Emmet J., primary, Kim, Hyunjae R., primary, Arcila, Maria E., primary, Barron, David, primary, Chakravarty, Debyani, primary, Gao, JianJiong, primary, Chang, Matthew T., primary, Ni, Andy, primary, Kundra, Ritika, primary, Jonsson, Philip, primary, Jayakumaran, Gowtham, primary, Gao, Sizhi Paul, primary, Johnsen, Hannah C., primary, Hanrahan, Aphrothiti J., primary, Zehir, Ahmet, primary, Rekhtman, Natasha, primary, Ginsberg, Michelle S., primary, Li, Bob T., primary, Yu, Helena A., primary, Paik, Paul K., primary, Drilon, Alexander, primary, Hellmann, Matthew D., primary, Reales, Dalicia N., primary, Benayed, Ryma, primary, Rusch, Valerie W., primary, Kris, Mark G., primary, Chaft, Jamie E., primary, Baselga, José, primary, Taylor, Barry S., primary, Schultz, Nikolaus, primary, Rudin, Charles M., primary, Hyman, David M., primary, Berger, Michael F., primary, Solit, David B., primary, Ladanyi, Marc, primary, and Riely, Gregory J., primary

Published
2023
Full Text
View/download PDF

15. Data from AKT1 E17K Inhibits Cancer Cell Migration by Abrogating β-Catenin Signaling

Author

Gao, Sizhi Paul, primary, Kiliti, Amber J., primary, Zhang, Kai, primary, Vasani, Naresh, primary, Mao, Ninghui, primary, Jordan, Emmet, primary, Wise, Hannah C., primary, Shrestha Bhattarai, Tripti, primary, Hu, Wenhuo, primary, Dorso, Madeline, primary, Rodrigues, James A., primary, Kim, Kwanghee, primary, Hanrahan, Aphrothiti J., primary, Razavi, Pedram, primary, Carver, Brett, primary, Chandarlapaty, Sarat, primary, Reis-Filho, Jorge S., primary, Taylor, Barry S., primary, and Solit, David B., primary

Published
2023
Full Text
View/download PDF

16. Supplementary Figures 1-12, Supplementary Tables 1-3 from AKT1 E17K Inhibits Cancer Cell Migration by Abrogating β-Catenin Signaling

Author

Gao, Sizhi Paul, primary, Kiliti, Amber J., primary, Zhang, Kai, primary, Vasani, Naresh, primary, Mao, Ninghui, primary, Jordan, Emmet, primary, Wise, Hannah C., primary, Shrestha Bhattarai, Tripti, primary, Hu, Wenhuo, primary, Dorso, Madeline, primary, Rodrigues, James A., primary, Kim, Kwanghee, primary, Hanrahan, Aphrothiti J., primary, Razavi, Pedram, primary, Carver, Brett, primary, Chandarlapaty, Sarat, primary, Reis-Filho, Jorge S., primary, Taylor, Barry S., primary, and Solit, David B., primary

Published
2023
Full Text
View/download PDF

17. Supplementary Figure 3 from Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies

Author

Jordan, Emmet J., primary, Kim, Hyunjae R., primary, Arcila, Maria E., primary, Barron, David, primary, Chakravarty, Debyani, primary, Gao, JianJiong, primary, Chang, Matthew T., primary, Ni, Andy, primary, Kundra, Ritika, primary, Jonsson, Philip, primary, Jayakumaran, Gowtham, primary, Gao, Sizhi Paul, primary, Johnsen, Hannah C., primary, Hanrahan, Aphrothiti J., primary, Zehir, Ahmet, primary, Rekhtman, Natasha, primary, Ginsberg, Michelle S., primary, Li, Bob T., primary, Yu, Helena A., primary, Paik, Paul K., primary, Drilon, Alexander, primary, Hellmann, Matthew D., primary, Reales, Dalicia N., primary, Benayed, Ryma, primary, Rusch, Valerie W., primary, Kris, Mark G., primary, Chaft, Jamie E., primary, Baselga, José, primary, Taylor, Barry S., primary, Schultz, Nikolaus, primary, Rudin, Charles M., primary, Hyman, David M., primary, Berger, Michael F., primary, Solit, David B., primary, Ladanyi, Marc, primary, and Riely, Gregory J., primary

Published
2023
Full Text
View/download PDF

18. Supplementary Figure 1 from Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies

Author

Jordan, Emmet J., primary, Kim, Hyunjae R., primary, Arcila, Maria E., primary, Barron, David, primary, Chakravarty, Debyani, primary, Gao, JianJiong, primary, Chang, Matthew T., primary, Ni, Andy, primary, Kundra, Ritika, primary, Jonsson, Philip, primary, Jayakumaran, Gowtham, primary, Gao, Sizhi Paul, primary, Johnsen, Hannah C., primary, Hanrahan, Aphrothiti J., primary, Zehir, Ahmet, primary, Rekhtman, Natasha, primary, Ginsberg, Michelle S., primary, Li, Bob T., primary, Yu, Helena A., primary, Paik, Paul K., primary, Drilon, Alexander, primary, Hellmann, Matthew D., primary, Reales, Dalicia N., primary, Benayed, Ryma, primary, Rusch, Valerie W., primary, Kris, Mark G., primary, Chaft, Jamie E., primary, Baselga, José, primary, Taylor, Barry S., primary, Schultz, Nikolaus, primary, Rudin, Charles M., primary, Hyman, David M., primary, Berger, Michael F., primary, Solit, David B., primary, Ladanyi, Marc, primary, and Riely, Gregory J., primary

Published
2023
Full Text
View/download PDF

19. Supplementary Figure 7 from Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies

Author

Jordan, Emmet J., primary, Kim, Hyunjae R., primary, Arcila, Maria E., primary, Barron, David, primary, Chakravarty, Debyani, primary, Gao, JianJiong, primary, Chang, Matthew T., primary, Ni, Andy, primary, Kundra, Ritika, primary, Jonsson, Philip, primary, Jayakumaran, Gowtham, primary, Gao, Sizhi Paul, primary, Johnsen, Hannah C., primary, Hanrahan, Aphrothiti J., primary, Zehir, Ahmet, primary, Rekhtman, Natasha, primary, Ginsberg, Michelle S., primary, Li, Bob T., primary, Yu, Helena A., primary, Paik, Paul K., primary, Drilon, Alexander, primary, Hellmann, Matthew D., primary, Reales, Dalicia N., primary, Benayed, Ryma, primary, Rusch, Valerie W., primary, Kris, Mark G., primary, Chaft, Jamie E., primary, Baselga, José, primary, Taylor, Barry S., primary, Schultz, Nikolaus, primary, Rudin, Charles M., primary, Hyman, David M., primary, Berger, Michael F., primary, Solit, David B., primary, Ladanyi, Marc, primary, and Riely, Gregory J., primary

Published
2023
Full Text
View/download PDF

20. Supplementary Figure 4 from Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies

Author

Jordan, Emmet J., primary, Kim, Hyunjae R., primary, Arcila, Maria E., primary, Barron, David, primary, Chakravarty, Debyani, primary, Gao, JianJiong, primary, Chang, Matthew T., primary, Ni, Andy, primary, Kundra, Ritika, primary, Jonsson, Philip, primary, Jayakumaran, Gowtham, primary, Gao, Sizhi Paul, primary, Johnsen, Hannah C., primary, Hanrahan, Aphrothiti J., primary, Zehir, Ahmet, primary, Rekhtman, Natasha, primary, Ginsberg, Michelle S., primary, Li, Bob T., primary, Yu, Helena A., primary, Paik, Paul K., primary, Drilon, Alexander, primary, Hellmann, Matthew D., primary, Reales, Dalicia N., primary, Benayed, Ryma, primary, Rusch, Valerie W., primary, Kris, Mark G., primary, Chaft, Jamie E., primary, Baselga, José, primary, Taylor, Barry S., primary, Schultz, Nikolaus, primary, Rudin, Charles M., primary, Hyman, David M., primary, Berger, Michael F., primary, Solit, David B., primary, Ladanyi, Marc, primary, and Riely, Gregory J., primary

Published
2023
Full Text
View/download PDF

21. Supplementary tables S1-4 from Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies

Author

Jordan, Emmet J., primary, Kim, Hyunjae R., primary, Arcila, Maria E., primary, Barron, David, primary, Chakravarty, Debyani, primary, Gao, JianJiong, primary, Chang, Matthew T., primary, Ni, Andy, primary, Kundra, Ritika, primary, Jonsson, Philip, primary, Jayakumaran, Gowtham, primary, Gao, Sizhi Paul, primary, Johnsen, Hannah C., primary, Hanrahan, Aphrothiti J., primary, Zehir, Ahmet, primary, Rekhtman, Natasha, primary, Ginsberg, Michelle S., primary, Li, Bob T., primary, Yu, Helena A., primary, Paik, Paul K., primary, Drilon, Alexander, primary, Hellmann, Matthew D., primary, Reales, Dalicia N., primary, Benayed, Ryma, primary, Rusch, Valerie W., primary, Kris, Mark G., primary, Chaft, Jamie E., primary, Baselga, José, primary, Taylor, Barry S., primary, Schultz, Nikolaus, primary, Rudin, Charles M., primary, Hyman, David M., primary, Berger, Michael F., primary, Solit, David B., primary, Ladanyi, Marc, primary, and Riely, Gregory J., primary

Published
2023
Full Text
View/download PDF

22. Supplementary Figure 2 from Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies

Author

Jordan, Emmet J., primary, Kim, Hyunjae R., primary, Arcila, Maria E., primary, Barron, David, primary, Chakravarty, Debyani, primary, Gao, JianJiong, primary, Chang, Matthew T., primary, Ni, Andy, primary, Kundra, Ritika, primary, Jonsson, Philip, primary, Jayakumaran, Gowtham, primary, Gao, Sizhi Paul, primary, Johnsen, Hannah C., primary, Hanrahan, Aphrothiti J., primary, Zehir, Ahmet, primary, Rekhtman, Natasha, primary, Ginsberg, Michelle S., primary, Li, Bob T., primary, Yu, Helena A., primary, Paik, Paul K., primary, Drilon, Alexander, primary, Hellmann, Matthew D., primary, Reales, Dalicia N., primary, Benayed, Ryma, primary, Rusch, Valerie W., primary, Kris, Mark G., primary, Chaft, Jamie E., primary, Baselga, José, primary, Taylor, Barry S., primary, Schultz, Nikolaus, primary, Rudin, Charles M., primary, Hyman, David M., primary, Berger, Michael F., primary, Solit, David B., primary, Ladanyi, Marc, primary, and Riely, Gregory J., primary

Published
2023
Full Text
View/download PDF

23. Supplementary Figure 6 from Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies

Author

Jordan, Emmet J., primary, Kim, Hyunjae R., primary, Arcila, Maria E., primary, Barron, David, primary, Chakravarty, Debyani, primary, Gao, JianJiong, primary, Chang, Matthew T., primary, Ni, Andy, primary, Kundra, Ritika, primary, Jonsson, Philip, primary, Jayakumaran, Gowtham, primary, Gao, Sizhi Paul, primary, Johnsen, Hannah C., primary, Hanrahan, Aphrothiti J., primary, Zehir, Ahmet, primary, Rekhtman, Natasha, primary, Ginsberg, Michelle S., primary, Li, Bob T., primary, Yu, Helena A., primary, Paik, Paul K., primary, Drilon, Alexander, primary, Hellmann, Matthew D., primary, Reales, Dalicia N., primary, Benayed, Ryma, primary, Rusch, Valerie W., primary, Kris, Mark G., primary, Chaft, Jamie E., primary, Baselga, José, primary, Taylor, Barry S., primary, Schultz, Nikolaus, primary, Rudin, Charles M., primary, Hyman, David M., primary, Berger, Michael F., primary, Solit, David B., primary, Ladanyi, Marc, primary, and Riely, Gregory J., primary

Published
2023
Full Text
View/download PDF

24. Supplementary Figure 1 from Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention

Author

Lowery, Maeve A., primary, Ptashkin, Ryan, primary, Jordan, Emmet, primary, Berger, Michael F., primary, Zehir, Ahmet, primary, Capanu, Marinela, primary, Kemeny, Nancy E., primary, O'Reilly, Eileen M., primary, El-Dika, Imane, primary, Jarnagin, William R., primary, Harding, James J., primary, D'Angelica, Michael I., primary, Cercek, Andrea, primary, Hechtman, Jaclyn F., primary, Solit, David B., primary, Schultz, Nikolaus, primary, Hyman, David M., primary, Klimstra, David S., primary, Saltz, Leonard B., primary, and Abou-Alfa, Ghassan K., primary

Published
2023
Full Text
View/download PDF

25. Supplementary Table 1 from Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention

Author

Lowery, Maeve A., primary, Ptashkin, Ryan, primary, Jordan, Emmet, primary, Berger, Michael F., primary, Zehir, Ahmet, primary, Capanu, Marinela, primary, Kemeny, Nancy E., primary, O'Reilly, Eileen M., primary, El-Dika, Imane, primary, Jarnagin, William R., primary, Harding, James J., primary, D'Angelica, Michael I., primary, Cercek, Andrea, primary, Hechtman, Jaclyn F., primary, Solit, David B., primary, Schultz, Nikolaus, primary, Hyman, David M., primary, Klimstra, David S., primary, Saltz, Leonard B., primary, and Abou-Alfa, Ghassan K., primary

Published
2023
Full Text
View/download PDF

26. Supplementary Information from ERCC2 Helicase Domain Mutations Confer Nucleotide Excision Repair Deficiency and Drive Cisplatin Sensitivity in Muscle-Invasive Bladder Cancer

Author

Li, Qiang, primary, Damish, Alexis W., primary, Frazier, Zoë, primary, Liu, David, primary, Reznichenko, Elizaveta, primary, Kamburov, Atanas, primary, Bell, Andrew, primary, Zhao, Huiyong, primary, Jordan, Emmet J., primary, Gao, S. Paul, primary, Ma, Jennifer, primary, Abbosh, Philip H., primary, Bellmunt, Joaquim, primary, Plimack, Elizabeth R., primary, Lazaro, Jean-Bernard, primary, Solit, David B., primary, Bajorin, Dean, primary, Rosenberg, Jonathan E., primary, D'Andrea, Alan D., primary, Riaz, Nadeem, primary, Van Allen, Eliezer M., primary, Iyer, Gopa, primary, and Mouw, Kent W., primary

Published
2023
Full Text
View/download PDF

27. supplemental tables and figures from Concurrent Alterations in EGFR-Mutant Lung Cancers Associated with Resistance to EGFR Kinase Inhibitors and Characterization of MTOR as a Mediator of Resistance

Author

Yu, Helena A., primary, Suzawa, Ken, primary, Jordan, Emmet, primary, Zehir, Ahmet, primary, Ni, Ai, primary, Kim, Ryan, primary, Kris, Mark G., primary, Hellmann, Matthew D., primary, Li, Bob T., primary, Somwar, Romel, primary, Solit, David B., primary, Berger, Michael F., primary, Arcila, Maria, primary, Riely, Gregory J., primary, and Ladanyi, Marc, primary

Published
2023
Full Text
View/download PDF

28. Supplemental Data (Figures and Tables) from DNA Damage Response and Repair Gene Alterations Are Associated with Improved Survival in Patients with Platinum-Treated Advanced Urothelial Carcinoma

Author

Teo, Min Yuen, primary, Bambury, Richard M., primary, Zabor, Emily C., primary, Jordan, Emmet, primary, Al-Ahmadie, Hikmat, primary, Boyd, Mariel E., primary, Bouvier, Nancy, primary, Mullane, Stephanie A., primary, Cha, Eugene K., primary, Roper, Nitin, primary, Ostrovnaya, Irina, primary, Hyman, David M., primary, Bochner, Bernard H., primary, Arcila, Maria E., primary, Solit, David B., primary, Berger, Michael F., primary, Bajorin, Dean F., primary, Bellmunt, Joaquim, primary, Iyer, Gopakumar, primary, and Rosenberg, Jonathan E., primary

Published
2023
Full Text
View/download PDF

31. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients

Author

Zehir, Ahmet, Benayed, Ryma, Shah, Ronak H, Syed, Aijazuddin, Middha, Sumit, Kim, Hyunjae R, Srinivasan, Preethi, Gao, Jianjiong, Chakravarty, Debyani, Devlin, Sean M, Hellmann, Matthew D, Barron, David A, Schram, Alison M, Hameed, Meera, Dogan, Snjezana, Ross, Dara S, Hechtman, Jaclyn F, DeLair, Deborah F, Yao, JinJuan, Mandelker, Diana L, Cheng, Donavan T, Chandramohan, Raghu, Mohanty, Abhinita S, Ptashkin, Ryan N, Jayakumaran, Gowtham, Prasad, Meera, Syed, Mustafa H, Rema, Anoop Balakrishnan, Liu, Zhen Y, Nafa, Khedoudja, Borsu, Laetitia, Sadowska, Justyna, Casanova, Jacklyn, Bacares, Ruben, Kiecka, Iwona J, Razumova, Anna, Son, Julie B, Stewart, Lisa, Baldi, Tessara, Mullaney, Kerry A, Al-Ahmadie, Hikmat, Vakiani, Efsevia, Abeshouse, Adam A, Penson, Alexander V, Jonsson, Philip, Camacho, Niedzica, Chang, Matthew T, Won, Helen H, Gross, Benjamin E, Kundra, Ritika, Heins, Zachary J, Chen, Hsiao-Wei, Phillips, Sarah, Zhang, Hongxin, Wang, Jiaojiao, Ochoa, Angelica, Wills, Jonathan, Eubank, Michael, Thomas, Stacy B, Gardos, Stuart M, Reales, Dalicia N, Galle, Jesse, Durany, Robert, Cambria, Roy, Abida, Wassim, Cercek, Andrea, Feldman, Darren R, Gounder, Mrinal M, Hakimi, A Ari, Harding, James J, Iyer, Gopa, Janjigian, Yelena Y, Jordan, Emmet J, Kelly, Ciara M, Lowery, Maeve A, Morris, Luc G T, Omuro, Antonio M, Raj, Nitya, Razavi, Pedram, Shoushtari, Alexander N, Shukla, Neerav, Soumerai, Tara E, Varghese, Anna M, Yaeger, Rona, Coleman, Jonathan, Bochner, Bernard, Riely, Gregory J, Saltz, Leonard B, Scher, Howard I, Sabbatini, Paul J, Robson, Mark E, Klimstra, David S, Taylor, Barry S, Baselga, Jose, Schultz, Nikolaus, Hyman, David M, Arcila, Maria E, Solit, David B, Ladanyi, Marc, and Berger, Michael F

Subjects
Cancer -- Genetic aspects -- Research, Gene mutation -- Research, Cancer metastasis -- Genetic aspects -- Development and progression, Biological sciences, Health
Abstract

Tumor molecular profiling is a fundamental component of precision oncology, enabling the identification of genomic alterations in genes and pathways that can be targeted therapeutically. The existence of recurrent targetable alterations across distinct histologically defined tumor types, coupled with an expanding portfolio of molecularly targeted therapies, demands flexible and comprehensive approaches to profile clinically relevant genes across the full spectrum of cancers. We established a large-scale, prospective clinical sequencing initiative using a comprehensive assay, MSK-IMPACT, through which we have compiled tumor and matched normal sequence data from a unique cohort of more than 10,000 patients with advanced cancer and available pathological and clinical annotations. Using these data, we identified clinically relevant somatic mutations, novel noncoding alterations, and mutational signatures that were shared by common and rare tumor types. Patients were enrolled on genomically matched clinical trials at a rate of 11%. To enable discovery of novel biomarkers and deeper investigation into rare alterations and tumor types, all results are publicly accessible., Author(s): Ahmet Zehir [1]; Ryma Benayed [1]; Ronak H Shah [1]; Aijazuddin Syed [1]; Sumit Middha [1]; Hyunjae R Kim [1]; Preethi Srinivasan [1]; Jianjiong Gao [2]; Debyani Chakravarty [2]; [...]

Published
2017
Full Text
View/download PDF

36. Abstract PS12-25: Patterns of treatment and outcomes in real world patients with advanced estrogen receptor positive breast cancer receiving palbociclib and endocrine therapy

Author

Prior, Lisa, primary, Skrobo, Darko, additional, Murray, Hazel, additional, Farooq, Abdul Rehman, additional, Horgan, Anne, additional, Calvert, Paula, additional, Jordan, Emmet, additional, McCaffrey, John, additional, Smyth, Lillian, additional, O'Connor, Miriam, additional, Higgins, Michaela, additional, Carney, Desmond, additional, Walshe, Janice, additional, Gullo, Giuseppe, additional, Crown, John, additional, and Kelly, Catherine M, additional

Published
2021
Full Text
View/download PDF

37. AKT1 E17K Inhibits Cancer Cell Migration by Abrogating β-Catenin Signaling

Author

Gao, Sizhi Paul, primary, Kiliti, Amber J., additional, Zhang, Kai, additional, Vasani, Naresh, additional, Mao, Ninghui, additional, Jordan, Emmet, additional, Wise, Hannah C., additional, Shrestha Bhattarai, Tripti, additional, Hu, Wenhuo, additional, Dorso, Madeline, additional, Rodrigues, James A., additional, Kim, Kwanghee, additional, Hanrahan, Aphrothiti J., additional, Razavi, Pedram, additional, Carver, Brett, additional, Chandarlapaty, Sarat, additional, Reis-Filho, Jorge S., additional, Taylor, Barry S., additional, and Solit, David B., additional

Published
2020
Full Text
View/download PDF

40. Harnessing Clinical Sequencing Data for Survival Stratification of Patients With Metastatic Lung Adenocarcinomas

Author

Shen, Ronglai, primary, Martin, Axel, additional, Ni, Ai, additional, Hellmann, Matthew, additional, Arbour, Kathryn C., additional, Jordan, Emmet, additional, Arora, Arshi, additional, Ptashkin, Ryan, additional, Zehir, Ahmet, additional, Kris, Mark G., additional, Rudin, Charles M., additional, Berger, Michael F., additional, Solit, David B., additional, Seshan, Venkatraman E., additional, Arcila, Maria, additional, Ladanyi, Marc, additional, and Riely, Gregory J., additional

Published
2019
Full Text
View/download PDF

41. Frequency and outcomes of brain metastases in patients withHER2‐mutant lung cancers

Author

Offin, Michael, primary, Feldman, Daniel, additional, Ni, Ai, additional, Myers, Mackenzie L., additional, Lai, W. Victoria, additional, Pentsova, Elena, additional, Boire, Adrienne, additional, Daras, Mariza, additional, Jordan, Emmet J., additional, Solit, David B., additional, Arcila, Maria E., additional, Jones, David R., additional, Isbell, James M., additional, Beal, Kathryn, additional, Young, Robert J., additional, Rudin, Charles M., additional, Riely, Gregory J., additional, Drilon, Alexander, additional, Tabar, Viviane, additional, DeAngelis, Lisa M., additional, Yu, Helena A., additional, Kris, Mark G., additional, and Li, Bob T., additional

Published
2019
Full Text
View/download PDF

42. Clinical haematological biomarkers: Derived neutrophil-to-lymphocyte ratio (dNLR), platelet-to-lymphocyte ratio (PLR), and prognostic nutritional index (PNI) and their relationship to survival outcomes in non small cell lung cancer (NSCLC) treated with immunotherapy: A multicenter review.

Author

Dennehy, Colum, primary, McMahon, Eileen, additional, Power, Derek Gerard, additional, O'Reilly, Seamus, additional, Collins, Dearbhaile Catherine, additional, O'Mahony, Deirdre, additional, Horgan, Anne M., additional, O'Connor, Miriam, additional, Jordan, Emmet, additional, Calvert, Paula, additional, and Bambury, Richard Martin, additional

Published
2019
Full Text
View/download PDF

43. ERCC2 Helicase Domain Mutations Confer Nucleotide Excision Repair Deficiency and Drive Cisplatin Sensitivity in Muscle-Invasive Bladder Cancer

Author

Li, Qiang, primary, Damish, Alexis W., additional, Frazier, Zoë, additional, Liu, David, additional, Reznichenko, Elizaveta, additional, Kamburov, Atanas, additional, Bell, Andrew, additional, Zhao, Huiyong, additional, Jordan, Emmet J., additional, Gao, S. Paul, additional, Ma, Jennifer, additional, Abbosh, Philip H., additional, Bellmunt, Joaquim, additional, Plimack, Elizabeth R., additional, Lazaro, Jean-Bernard, additional, Solit, David B., additional, Bajorin, Dean, additional, Rosenberg, Jonathan E., additional, D'Andrea, Alan D., additional, Riaz, Nadeem, additional, Van Allen, Eliezer M., additional, Iyer, Gopa, additional, and Mouw, Kent W., additional

Published
2019
Full Text
View/download PDF

45. Frequency and outcomes of brain metastases in patients with HER2-mutant lung cancers.

Author

Offin, Michael, Feldman, Daniel, Ni, Ai, Myers, Mackenzie L., Lai, W. Victoria, Pentsova, Elena, Boire, Adrienne, Daras, Mariza, Jordan, Emmet J., Solit, David B., Arcila, Maria E., Jones, David R., Isbell, James M., Beal, Kathryn, Young, Robert J., Rudin, Charles M., Riely, Gregory J., Drilon, Alexander, Tabar, Viviane, and DeAngelis, Lisa M.

Subjects
GENETIC mutation, BRAIN metastasis, LUNG cancer, EPIDERMAL growth factor receptors, PARANEOPLASTIC syndromes
Abstract

Background: Mutations in human epidermal growth factor receptor 2 (HER2; also known as ERBB2) are found in approximately 2% of lung adenocarcinomas. The frequency and clinical course of brain metastases in this oncogenic subset are ill defined.Methods: Baseline and subsequent development of brain metastases was evaluated in consecutive patients with HER2-mutant (n = 98), epidermal growth factor receptor (EGFR)-mutant (n = 200), and KRAS-mutant lung cancers (n = 200).Results: At metastatic diagnosis, the odds ratio (ORs) for brain metastases was similar for patients whose tumors harbored HER2 mutations (19%) in comparison with patients with KRAS mutations (24%; OR for HER2 vs KRAS, 0.7; P = .33) but lower compared to patients with EGFR mutations (31%; OR for HER2 vs EGFR, 0.5; P = .03). Patients with lung cancer and HER2 mutations developed more brain metastases on treatment than patients with KRAS mutations (28% vs 8%; hazard ratio [HR], 5.2; P < .001) and trended more than patients with EGFR mutations (28% vs 16%; HR, 1.7; P = .06). Patients with HER2 YVMA mutations also developed more brain metastases on treatment than patients with KRAS mutations (HR, 5.9; P < .001). The median overall survival (OS) was shorter for patients with HER2-mutant (1.6 years; P < .001) or KRAS-mutant lung cancers (1.1 years; P < .001) than patients with EGFR-mutant lung cancers (3.0 years). Brain metastases occurred in 47% of patients with HER2-mutant lung cancers, which imparted shorter OS (HR, 2.7; P < .001).Conclusions: These data provide a framework for brain imaging surveillance in patients with HER2-mutant lung cancers and underpin the need to develop HER2-targeted agents with central nervous system activity. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

47. Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention

Author

Lowery, Maeve A., primary, Ptashkin, Ryan, additional, Jordan, Emmet, additional, Berger, Michael F., additional, Zehir, Ahmet, additional, Capanu, Marinela, additional, Kemeny, Nancy E., additional, O'Reilly, Eileen M., additional, El-Dika, Imane, additional, Jarnagin, William R., additional, Harding, James J., additional, D'Angelica, Michael I., additional, Cercek, Andrea, additional, Hechtman, Jaclyn F., additional, Solit, David B., additional, Schultz, Nikolaus, additional, Hyman, David M., additional, Klimstra, David S., additional, Saltz, Leonard B., additional, and Abou-Alfa, Ghassan K., additional

Published
2018
Full Text
View/download PDF

48. Concurrent Alterations in EGFR-Mutant Lung Cancers Associated with Resistance to EGFR Kinase Inhibitors and Characterization of MTOR as a Mediator of Resistance

Author

Yu, Helena A., primary, Suzawa, Ken, additional, Jordan, Emmet, additional, Zehir, Ahmet, additional, Ni, Ai, additional, Kim, Ryan, additional, Kris, Mark G., additional, Hellmann, Matthew D., additional, Li, Bob T., additional, Somwar, Romel, additional, Solit, David B., additional, Berger, Michael F., additional, Arcila, Maria, additional, Riely, Gregory J., additional, and Ladanyi, Marc, additional

Published
2018
Full Text
View/download PDF

49. Brain Metastases in Pancreatic Ductal Adenocarcinoma: Assessment of Molecular Genotype–Phenotype Features—An Entity With an Increasing Incidence?

Author

Jordan, Emmet J., primary, Lowery, Maeve A., additional, Basturk, Olca, additional, Allen, Peter J., additional, Yu, Kenneth H., additional, Tabar, Viviane, additional, Beal, Kathryn, additional, Reidy, Diane L., additional, Yamada, Yoshiya, additional, Janjigian, Yelena, additional, Abou-Alfa, Ghassan K., additional, and O'Reilly, Eileen M., additional

Published
2018
Full Text
View/download PDF

50. Frequency of brain metastases and outcomes in patients with HER2-, KRAS-, and EGFR-mutant lung cancers.

Author

Kris, Mark G., primary, Offin, Michael David, additional, Feldman, Daniel L., additional, Ni, Ai, additional, Lai, Wei-Chu Victoria, additional, Arbour, Kathryn Cecilia, additional, Daras, Mariza, additional, Pentsova, Elena, additional, DeAngelis, Lisa Marie, additional, Beal, Kathryn, additional, Young, Robert J., additional, Jordan, Emmet, additional, Arcila, Maria E., additional, Jones, David Randolph, additional, Isbell, James M., additional, Riely, Gregory J., additional, Drilon, Alexander E., additional, Yu, Helena Alexandra, additional, and Li, Bob T., additional

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results